KhosrowMahdaviMDFACP
Oncology • Costa Mesa, CAClinical Professor Hematology,Oncology, University of California Irvine.
Dr. Mahdavi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1640 Newport Blvd
Ste 400
Costa Mesa, CA 92627Phone+1 949-999-2400Fax+1 949-999-2405- Is this information wrong?
Education & Training
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 1978 - 1979
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1977
Loyola University Medical Center/Trinity-Mercy ChicagoResidency, Internal Medicine, 1974 - 1976
Grant Hospital of ChicagoResidency, Family Medicine, 1973 - 1974- Grant Hospital of ChicagoInternship, Transitional Year, 1972 - 1973
Tehran University of Medical Sciences School of MedicineClass of 1969
Certifications & Licensure
IL State Medical License 1974 - Present
CA State Medical License 1979 - 2024
OH State Medical License 1977 - 1979- American Board of Internal Medicine Internal Medicine
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 1995
Publications & Presentations
PubMed
- 18 citationsDendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent ...Robert O. Dillman, Edward F. McClay, Neil M. Barth, Thomas Amatruda, Lee S. Schwartzberg, Khosrow Mahdavi, Cristina de Leon, Robin E. Ellis, Carol DePriest> ;Cancer Biotherapy & Radiopharmaceuticals. 2015 Jun 1
- 16 citationsShould high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Khosrow Mahdavi, Stephanie E. McClure> ;Cancer Biotherapy & Radiopharmaceuticals. 2012 Jul 17
- 7 citationsShould High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Warren H. Fong, Khosrow Mahdavi, Stephanie E. McClure> ;Cancer Biotherapy & Radiopharmaceuticals. 2011 Jul 5
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Hoag Memorial Hospital PresbyterianNewport Beach, California
UCI HealthOrange, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
